ADRB3 and metabolic disease: Although mirabegron has been found to induce BAT activity as measured by 18FFDG-PET/CT (99), increase non-esterified fatty acids by up to 68%, and boost resting energy expenditure by up to 5.8% (100) in humans, no β3-AR agonists has been approved to treat metabolic disorders thus far.